Regencell Bioscience Holdings Limited (RGC)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regencell Bioscience Holdings Limited (“Regencell” or “the Company”) (NASDAQ: RGC). Investors who purchased Regencell securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Regencell has violated federal securities laws.
Regencell Investigation Details
On October 31, 2025, Regencell disclosed in a filing with the U.S. Securities and Exchange Commission that “following recent volatility in the market for our Ordinary Shares, the Company received correspondence and a subpoena from the U.S. Department of Justice (‘DOJ’), indicating that the DOJ is conducting an investigation into the trading in our Ordinary Shares.” Regencell said that “[t]he DOJ has requested the production of documents and communications concerning these and other corporate operational, financial and accounting matters” and that the Company “expect[s] to continue to incur significant legal costs and other expenses in connection with responding to the investigation” and “may be required to pay fines, penalties, damages or settlement costs in excess of our insurance coverage, if any, related to the investigation.” Following this news, Regencell’s stock price fell $3.09 per share, or 18.56%, to close at $13.56 per share on November 3, 2025.
What’s Next for Regencell Investors?
If you are aware of any facts relating to this investigation or purchased Regencell securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Regencell Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Regencell Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.